Powered by MOMENTUM MEDIA

Despite positive developments, uncertainties remain for financial markets

Nicholas Demko
— 1 minute read

Markets are still underappreciating key elements of the recovery and the duration of immunity, so understanding how companies are positioning themselves for long-term growth is key, writes MFS Investment Management’s Nicholas Demko.

Nicholas Demko

The effectiveness of COVID-19 vaccines under development, at around 95 per cent, is much better than what we had expected; seasonal flu vaccine effectiveness has been around 50 per cent in the US. At the same time, COVID-19 case counts are taking off, both in the US and many other regions globally, and the trajectory is concerning from both a societal and financial markets standpoint.

This leaves financial markets in a continued period of uncertainty and volatility. The likelihood of recessionary tail risks (which is always present in financial markets) feels elevated today, especially when you consider that stocks are at near-record-high valuations, and corporations have near-record-high debt levels and margins.

Advertisement
Advertisement

However, interest rates are low, consumer balance sheets are in good shape and central banks continue to be accommodative, so if we are able to navigate through the tail risks until the vaccine is widely distributed in a year or two, we may be left with a good setup for equities that offer attractive investment opportunities for long-term investors.

The market is still underappreciating key elements of the recovery

There is still much we do not know about the COVID-19 virus and the vaccines in development, such as the long-term safety of those vaccines (which is getting a lot of attention right now). However, the market is really underappreciating the duration of immunity. How long will the vaccine protect you? Many experts today think that somewhere between one and three years of immunity is reasonable, but the reality is that we do not know. If immunity lasts only a few months or the virus mutates, the current generation of vaccines might prove ineffective.

At the industry and sector level, there are unknowns related to long-term consumer preference, i.e. we have seen consumer preferences change during the pandemic out of necessity, but they might actually be a better way to do things over the longer term. Areas such as airlines and cruises and hotels are the ones in the headlines, but consumer preference changes could be much more pervasive across every industry.

A return to a relatively normal lifestyle is not going to happen with the flip of a switch. There will be a slow progression; lower-risk activities will likely come back faster than higher-risk.

The winners and losers are still to be determined, and will be over the next few years

There are still a lot of unknowns, but we are starting to see some opportunities in companies where management can really capitalise on this brief period of rather rapid change by investing in the future and setting up their companies to be fundamentally better off over the next decade or longer.

An example is in the life science tools and diagnostics equipment manufacturers, which are companies that manufacture the highly complex instrumentation and equipment that we are using to combat this virus, including COVID-19 diagnostic test manufacturers. Many of these companies are reinvesting COVID-19-related profits in talent and technology that can enable new scientific discoveries. Where we have confidence in the capital allocation abilities of management, we see opportunity for these companies to take share in a growing pie of global life science research and development spend. We find this space attractive compared with the vaccine manufactures themselves, where higher levels of competition are likely to make long-term profitability more challenging.

Another example is in digital health and telemedicine. The pandemic has exposed some inefficiencies in the way healthcare is delivered globally. With the use of technology such as on-demand video with a physician, remote monitoring of patients via an internet-connected medical device etc, better-quality care can be delivered in a more convenient, lower-cost manner in certain circumstances. There are a few companies that are enabling this digital transformation of healthcare that we find attractive today.

More generally, companies are using technology differently. They are connecting with their customers and suppliers differently, and every facet of operations is being impacted in some way by the pandemic. Some of the new ways of doing things are going to be less effective than prior ways, but other ways are likely to be better. Understanding how companies are positioning themselves for long-term growth is key to investing.

Nicholas Demko, equity research analyst, MFS Investment Management

 

Despite positive developments, uncertainties remain for financial markets
Nicholas Demko
ID logo

 

related articles

promoted stories

Website Notifications

Get notifications in real-time for staying up to date with content that matters to you.